Cargando…

Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder

AIMS AND OBJECTIVES: The incidence of bladder malignancy is increasing worldwide and the projected rise is 28% by 2010 for both sexes (WHO). Though intravesical adjuvant therapy with BCG is superior to any other immunotherapeutic/chemotherapeutic agent in reducing tumor recurrences and disease progr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohanty, N. K., Nayak, Rajiba L., Vasudeva, Pawan, Arora, R. P.
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2008
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684230/ https://www.ncbi.nlm.nih.gov/pubmed/19468358 http://dx.doi.org/10.4103/0970-1591.35759

Ejemplares similares

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder
por: Elzein, Fatehi, et al.
Publicado: (2016)

The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: A pilot study
por: Vasudeva, Pawan, et al.
Publicado: (2008)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma
por: Ord, J J, et al.
Publicado: (2005)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Intravesical real-time imaging and staging of bladder cancer: Use of optical coherence tomography
por: Sengottayan, Vengatesh K., et al.
Publicado: (2008)

Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-α and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model
por: Xiao, Zhengwen, et al.
Publicado: (2011)

Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation
por: Karavana, Sinem Yaprak, et al.
Publicado: (2018)

Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU Group.
por: Newling, D.
Publicado: (1990)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer
por: Mackel, Charles E, et al.
Publicado: (2016)

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma
por: Doroud, Delaram, et al.
Publicado: (2022)

Intravesical gemcitabine as bladder‐preserving treatment for BCG unresponsive non‐muscle‐invasive bladder cancer. Results from a single‐arm, open‐label study
por: Hurle, Rodolfo, et al.
Publicado: (2020)

Complete response to intravesical gemcitabine in non‐muscle invasive bladder cancer patient after BCG failure: A case report and literature review
por: Nahhat, Fouad, et al.
Publicado: (2022)

Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience
por: Mohanty, N. K., et al.
Publicado: (2008)

Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG
Publicado: (2015)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
por: Vilares, Ana T., et al.
Publicado: (2022)

Pott's disease post intravesical BCG
por: Jain, Anika
Publicado: (2023)

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer
por: Bevers, R F M, et al.
Publicado: (2004)

Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
por: Han, Mi Ah, et al.
Publicado: (2021)

Pott’s Disease Caused by Mycobacterium bovis Following Intravesical BCG Therapy for Bladder Cancer
por: Jones, Zachary, et al.
Publicado: (2017)

Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
por: Wadhwani, Aman, et al.
Publicado: (2018)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
por: Moreo, Eduardo, et al.
Publicado: (2022)

Haemophagocytic lymphohistiocytosis after intravesical BCG administration for bladder cancer presenting with multiorgan failure
por: Liatsos, G. D., et al.
Publicado: (2023)

A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF
por: Hu, Zhiming, et al.
Publicado: (2010)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
por: Prasanna, Thiru, et al.
Publicado: (2017)

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Renal Tuberculosis Following Intravesical Bacillus Calmette–Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer
por: Bajramovic, Senad, et al.
Publicado: (2020)

Correction to: Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
por: Wadhwani, Aman, et al.
Publicado: (2019)

SAT-666 Possible Amelioration of Diabetic State After Intravesical BCG Instillations for Bladder Cancer
por: Havranova, Jana, et al.
Publicado: (2020)

Case Report with Systematic Literature Review on Vascular Complications of BCG Intravesical Therapy for Bladder Cancer
por: King, Brianna, et al.
Publicado: (2022)

Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyo with GMCSF+IFN α Induce Systemic Immunity in a Murine Orthotopic Bladder Cancer Model
por: Tham, Sin Mun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ed62ts0oqcf3qs6cfs0li8jppa